Results 31 to 40 of about 2,262 (198)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +2 more sources

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2016
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV).
Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song   +3 more
doaj   +3 more sources

EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1 [PDF]

, 2018
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them
Takuma Ajimine, Shigetoshi Ohshima, Takashi Goto, Masafumi Komatsu, Kunio Nakane, Hitoshi Yagisawa, Mitsuo Goto, Kou NAKAJIMA, Masato Miura, Masato Funaoka, Takao HOSHINO, Tomoyuki Kuramitsu, Yuukou Fujishima, Daisuke WATANABE, Daisuke Segawa, Masaaki Inomata, Katsunori IIJIMA   +16 more
openalex   +3 more sources

Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study. [PDF]

Cancer Med
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Itoh S, Iseda N, Yoshizumi T, Ide T, Noshiro H, Sakai H, Hisaka T, Nakashima M, Nagano H, Okabe H, Hayashi H, Miyoshi A, Kitahara K, Takami Y, Nanashima A, Kuroki T, Endo Y, Okamoto K, Kajiwara M, Sakoda M, Beppu T, Takatsuki M, Eguchi S.   +22 more
europepmc   +2 more sources

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target-Bound. [PDF]

Chemistry
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Wieske LHE, Bu G, Erdélyi M, Kihlberg J, Gonen T, Danelius ER.   +5 more
europepmc   +2 more sources

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study. [PDF]

Medicina (Kaunas), 2023
Yoon JH, Kim SE, Cho SH, Kim GA, Park Y, Park JW, Kang SH, Lee YS, Kim JH.   +8 more
europepmc   +3 more sources

Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

Gut and Liver, 2018
Background/AimsChanges in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years.
Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi   +10 more
doaj   +3 more sources

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C. [PDF]

Int J Hepatol
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Tawara S, Watanabe A, Yamaguchi J, Omi M, Miyazaki T, Taguchi H, Kiyota R, Yamai T, Kawai S, Inoue T, Yakushijin T.   +10 more
europepmc   +2 more sources

Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. [PDF]

PLoS ONE, 2016
The aim of this study was to evaluate the efficacy of daclatasvir plus asunaprevir therapy in patients infected with hepatitis C virus and determine its relevance to resistant variants.A total of 629 consecutive patients infected with hepatitis C virus ...
Tatsuya Ide, Yuichiro Eguchi, Masaru Harada, Kunihide Ishii, Masaru Morita, Yasuyo Morita, Gen Sugiyama, Hirofumi Fukushima, Yoichi Yano, Kazunori Noguchi, Hiroki Nakamura, Junjiro Hisatomi, Hiroto Kumemura, Miki Shirachi, Shinji Iwane, Michiaki Okada, Yuichi Honma, Teruko Arinaga-Hino, Ichiro Miyajima, Kei Ogata, Reiichiro Kuwahara, Keisuke Amano, Toshihiro Kawaguchi, Ryoko Kuromatsu, Takuji Torimura, DAAs Multicenter Study Group   +25 more
doaj   +1 more source

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source